CAMBRIDGE, Mass., Aug. 13,
2024 /PRNewswire/ -- Tevard Biosciences,
Inc., a privately held biotechnology company pioneering tRNA-based
therapies to cure a broad range of genetic diseases, today
announced that it will be moving its corporate headquarters to
Lilly Gateway Labs (LGL) located in the Seaport District in
Boston. Tevard was selected to
join the LGL community based on its cutting-edge tRNA platform
technologies and promising programs for neurological disorders,
cardiology, and muscular dystrophies.
Gateway Labs is housed within the Lilly Seaport Innovation
Center, Eli Lilly and Company's newest R&D facility. At LGL,
selected companies can take advantage of shared resources,
operational support, and leverage Lilly's innovators, leaders, and
global network of investors and preferred partners. While at LGL,
Tevard will retain complete strategic independence, as well as
ownership of its assets and intellectual property.
"We are honored to have been selected to join this best-in-class
innovation hub and have the opportunity to continue building our
company and advance our programs into the clinic within this
collaborative environment," said Daniel
Fischer, Co-founder, President, and CEO of Tevard
Biosciences. "The Gateway Labs model provides a unique support
system for companies at our stage, enabling us to stay true to our
scientific mission while gaining the advantage of direct access to
Lilly's scientific and operational expertise, and customized drug
development support, which will help fuel our next stage of
growth."
Tevard's pre-clinical pipeline is based on novel Suppressor tRNA
technology that treats diseases caused by premature stop codons by
restoring full-length functional proteins. The Company's lead
program is focused on genetic epilepsies, and its pipeline includes
cardiology indications, and Duchenne muscular dystrophy (DMD)
through an ongoing research collaboration with Vertex
Pharmaceuticals Incorporated.
About Tevard Biosciences
Tevard Biosciences is pioneering tRNA-based and other
mRNA-modulating therapies to cure a broad range of genetic
diseases. The privately held biotechnology company was founded by
renowned scientists along with life science executives and
entrepreneurs who are also fathers of children with Dravet
Syndrome, a rare genetic disease. Tevard is advancing the use of
its novel Suppressor tRNA platform in neurological disorders, heart
disease, and muscular dystrophies. The company has an ongoing
research collaboration with Vertex Pharmaceuticals Incorporated
aimed at creating new tRNA-based therapies for patients with
Duchenne muscular dystrophy (DMD). For more information, please
visit www.tevard.com.
CONTACT:
Catherine Collier Kyroulis
Scient PR
(917) 886-5586
media@tevard.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tevard-biosciences-to-move-corporate-headquarters-to-lilly-gateway-labs-in-bostons-seaport-302220515.html
SOURCE Tevard Biosciences